Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adoptive Immunotherapy for HLA_A2 Genotype gp100 Positive Malignant Melanoma With GPA-TriMAR-T Cell

NCT03649529 is registered in ClinicalTrials.gov with Timmune Biotech Inc. as lead sponsor.

NCT NCT03649529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03649529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adoptive Immunotherapy for HLA_A2 Genotype gp100 Positive Malignant Melanoma With GPA-TriMAR-T Cell
Lead sponsor
Timmune Biotech Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
September 27, 2018
Completion date
January 1, 2022
Enrollment
6 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma